“The apprehension with using non IID listed ingredients is justified as it truly is unattainable To judge if FDA would discover the ‘novel excipient’ Protected for use in the drug products as there is not any outlined approach for analysis and approval of excipients. The FDA guidance on ‘Nonclinical https://deborahg738uch6.wikisona.com/user